Nico Corporation, an Indianapolis, IN-based medical device company, completed a $12.5m capital raise.
The round was led by RC Capital, with participation from existing investors.
The company intends to use the funds to scale the business and leverage continued progress on its recently completed adaptive clinical trial for intracerebral hemorrhage (ICH) and new partnership in functional precision oncology for patients with deadly treatment-resistant GBM.
Led by Jim Pearson, president and CEO, Nico is a medical device innovator creating a new reality in neurosurgery through its MIS technologies. The company has led the MIS neurosurgical field for over a decade with its set of technologies that do not require traditional methods of cutting through the brain to access abnormalities deep below the surface, but instead use the natural folds of the brain to reach abnormalities. Other technologies in its product family allow for safe removal of abnormalities or hemorrhages in a modern surgical suite, as well as biological preservation of tumor tissue for molecular profiling – enabling improved accuracy for today’s precision medicine treatments.
FinSMEs
27/10/2022